Biochemical and imaging markers in patients with thalassaemia

Maria Vlachou; Vasileios Kamperidis; George Giannakoulas; Theodoros Karamitsos; Efthymia Vlachaki; Haralambos Karvounis

doi:10.1016/j.hjc.2020.04.012

Biochemical and imaging markers in patients with thalassaemia

Hellenic J Cardiol. 2021 Jan-Feb;62(1):4-12. doi: 10.1016/j.hjc.2020.04.012. Epub 2020 May 6.

Authors

Maria Vlachou¹, Vasileios Kamperidis², George Giannakoulas¹, Theodoros Karamitsos¹, Efthymia Vlachaki³, Haralambos Karvounis¹

Affiliations

¹ 1(st) Cardiology Department, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
² 1(st) Cardiology Department, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece. Electronic address: vkamperidis@outlook.com.
³ Thalassaemia Unit, Ippokratio University Hospital, Thessaloniki, Greece.

PMID: 32387594
DOI: 10.1016/j.hjc.2020.04.012

Abstract

Beta-thalassaemia is a genetic disease with different clinical aspects, which can lead to heart failure with a multifactorial mechanism. Over the last years, growing interest has been reported for biomarkers that may help in the diagnosis, staging and prognosis of heart disease at an early stage, in patients with beta-thalassaemia. This review will highlight the current clinical value of cardiac biomarkers in patients with beta-thalassaemia and the ongoing research for a possible expanded future use.

Keywords: beta-thalassaemia; biomarkers; heart failure.

Publication types

Review

MeSH terms

Biomarkers
Heart Failure* / diagnosis
Humans
Prognosis
Thalassemia* / diagnosis
beta-Thalassemia* / diagnosis

Substances

Biomarkers